Evidence map›Paper›PMID 42446976›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Targeted α-synuclein mRNA degradation by PMO-based RNA-degrading chimeras.

Ning Wang, Shalakha Hegde, Zhichao Tang, Haiqing Liu, Gang Feng, Lili Niu, Bo Liu, Hanyu Li, Xiaodi Zhang, Kundlik Gadhave and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Ning Wang *Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-3410-8509
Shalakha Hegde *Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Zhichao Tang *Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Haiqing Liu *Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Gang FengNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Lili NiuNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0009-0000-7543-9526
Bo LiuDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0003-0342-8144
Hanyu LiNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Xiaodi ZhangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Kundlik GadhaveNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0003-4530-4772
Ramhari KumbharNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-8975-2502
Lan JiangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Yuqi LiuNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Maxwell LuoNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0009-0002-3290-5763
Shu ZhangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Ted M DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-6459-0893
Alexander PantelyatSection of Genetic Medicine, Department of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL 60637.ORCID 0000-0002-6427-7485
Liana S RosenthalSection of Genetic Medicine, Department of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL 60637.
Mingyao YingSection of Genetic Medicine, Department of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL 60637.
Xiaobo Mao *Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0001-6587-556X
Jingxin Wang *Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-9414-4093

Funding

Modulating gene expression by RNA-targeting chimerasR35GM147498 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Jingxin Wang · 2022 to 2026
$2.1M
HHS | National Institutes of Health (NIH) R35GM147498Maryland Stem Cell Research Fund (MSCRF) 2019-MSCRFD-4292Maryland Stem Cell Research Fund (MSCRF) 2024-MSCRFD-6394NIGMS NIH HHS R35 GM147498Parkinson's Foundation (PF) PF-IMP-1045798Parkinson's Foundation (PF) PF-JFA-1933
6 · The paper itself

Abstract

α-Synucleinopathies are devastating neurodegenerative diseases characterized by pathological accumulation of a neuronal protein, α-synuclein (αSyn). Lowering soluble αSyn levels is a promising therapeutic strategy to limit aggregation and neurotoxicity, but directly targeting this protein is hindered by its intrinsically disordered structure and other factors, such as its conformational heterogeneity and intracellular drug delivery barriers. Consequently, increasing attention has been directed toward targeting the

Indexed as

alpha-SynucleinMorpholinosRNA, MessengerRNA StabilityAnimalsEndoribonucleasesHEK293 CellsHumansMiceNeurons2-5A-dependent ribonucleasealpha-SynucleinEndoribonucleasesMorpholinosRNA, MessengerParkinson’s diseasephosphorodiamidate morpholino oligomer (PMO)RNA-degrading chimeraRNase Lα-synuclein

Identifiers

PMID42446976
PMCPMC13389697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.